[go: up one dir, main page]

UY26218A1 - COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.- - Google Patents

COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.-

Info

Publication number
UY26218A1
UY26218A1 UY26218A UY26218A UY26218A1 UY 26218 A1 UY26218 A1 UY 26218A1 UY 26218 A UY26218 A UY 26218A UY 26218 A UY26218 A UY 26218A UY 26218 A1 UY26218 A1 UY 26218A1
Authority
UY
Uruguay
Prior art keywords
combination
inhibitors
hmg
coa reductase
medicines
Prior art date
Application number
UY26218A
Other languages
Spanish (es)
Inventor
Rudi Grutzmann
Ulrich Muller
Hilmar Bischoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26218A1 publication Critical patent/UY26218A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de una combinación de al menos un inhibidor de MTP seleccionado ( componente A ) y un inhibidor de HMg - Coa reductasa ( componente B ) para la lucha contra enfermedades del sistema cardiocirculatorio, a medicamentos que contienen esta combinación y a su obtención.The invention relates to the use of a combination of at least one selected MTP inhibitor (component A) and an HMg-Coa reductase inhibitor (component B) for the fight against diseases of the cardiovascular system, drugs containing this combination and their obtaining.

UY26218A 1999-06-25 2000-06-23 COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.- UY26218A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor

Publications (1)

Publication Number Publication Date
UY26218A1 true UY26218A1 (en) 2001-01-31

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26218A UY26218A1 (en) 1999-06-25 2000-06-23 COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.-

Country Status (12)

Country Link
EP (1) EP1196194A2 (en)
JP (1) JP2003503342A (en)
AR (1) AR028996A1 (en)
AU (1) AU5680900A (en)
CA (1) CA2376881A1 (en)
DE (1) DE19929065A1 (en)
DO (1) DOP2000000022A (en)
GT (1) GT200000099A (en)
PE (1) PE20010302A1 (en)
SV (1) SV2004000109A (en)
UY (1) UY26218A1 (en)
WO (1) WO2001000183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
CN101838218A (en) * 2002-02-28 2010-09-22 日本烟草产业株式会社 Ester compound and pharmaceutical use of the same
WO2005021486A1 (en) 2003-08-29 2005-03-10 Japan Tobacco Inc. Ester derivative and medicinal use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (en) * 2018-08-08 2018-12-21 中山大学 A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (en) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indole and -azaindole derivatives
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19615265A1 (en) * 1996-04-18 1997-12-04 Bayer Ag New pyridazino, pyrimido, pyrazino and triazinoindoles
CA2272719C (en) * 1996-11-27 2002-10-01 Pfizer Limited Apo b-secretion/mtp inhibitory amides
EP1024804A4 (en) * 1997-05-01 2001-03-21 Bristol Myers Squibb Co Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
DOP2000000022A (en) 2008-08-15
EP1196194A2 (en) 2002-04-17
DE19929065A1 (en) 2000-12-28
AR028996A1 (en) 2003-06-04
AU5680900A (en) 2001-01-31
WO2001000183A2 (en) 2001-01-04
GT200000099A (en) 2001-12-13
SV2004000109A (en) 2004-05-07
PE20010302A1 (en) 2001-04-12
CA2376881A1 (en) 2001-01-04
WO2001000183A3 (en) 2001-05-10
JP2003503342A (en) 2003-01-28

Similar Documents

Publication Publication Date Title
BRPI0413363A (en) dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
PA8523901A1 (en) PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE ESTER CHOLESTERILE TRANSFER PROTEIN
DOP2000000022A (en) COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES.
CL2017001847A1 (en) A solid pharmaceutical dosage formulation
PA8564901A1 (en) PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE CHOLESTERILE ESTERES TRANSFER PROTEIN
PA8513601A1 (en) PHARMACEUTICAL COMPOSITIONS OF GLUCOGENOPHOSPHORILASE INHIBITORS
BR0317715A (en) Compositions and processes of use of collajolie
CY1120313T1 (en) MEDICINAL COMPOSITION FOR LEATHER USE TO TREAT PREVENTION WHICH INCLUDES Vitamin D And Corticosteroids
BR0012046A (en) Heterocyclic compound, pharmaceutical composition, inhibitor of activation of ap-1 or an inhibitor of activation of nf-kappab, inhibitor of the production of inflammatory cytokine, and inhibitor of the production of matrix metalloprotease or inhibitor of the expression of inflammatory cell adhesion factor
EE04990B1 (en) Pharmaceutical compositions containing an HMG reductase inhibitor, their use and method of preparation
UY26092A1 (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES
ES2188177T3 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, WHICH INCLUDES PROPIONIL-L-CARNITINE AND GENISTEINE.
EP1510221A4 (en) PREVENTIVE AND / OR THERAPEUTIC MEANS FOR SUBJECTS HAVING THE EXPRESSION OR ACTIVATION OF HER2 AND / OR EGFR
AR015379A1 (en) ASCORBIL-FOSFORIL-CHOLESTEROL
BRPI0410555A (en) solid preparation
BRPI0507654A (en) pharmaceutical composition comprising a benzodiazepine derivative and an rsv fusion protein inhibitor
WO2007053641A3 (en) A-type procyanidins and inflammation
BR0110506A (en) Use of il-18 inhibitors for the treatment and / or prevention of atherosclerosis.
BR0213181A (en) Cox-2 inhibitor combinations
WO2003057205A3 (en) Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
DK0991424T3 (en) Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor
UY27753A1 (en) PHARMACEUTICAL FORMULATION THAT MELATONINE INCLUDES.
EA199901043A1 (en) PHARMACEUTICAL TRANSFERASE INHIBITORS IN A COMBINATION WITH HMG-CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT
WO2001000184A3 (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
ATE418613T1 (en) ANTIMICROBIAL COMPOSITIONS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110721